Physician profile
Oren E Bernheim
NPI 1639338783
$12,889.31
in general payments reported to CMS, 2019-2025
35 companies · $1,059 in 2025
The $1,059 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,647 · 2020: $181 · 2021: $421 · 2022: $733 · 2023: $771 · 2024: $1,078 · 2025: $1,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,871 · Education: $36.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,870.83 |
| Education | $36.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $8,327.22 | 2019-2025 | |
| Abbvie INC. | $1,413.30 | 2019-2025 | Linzess, Skyrizi, Mavyret |
| Takeda Pharmaceuticals U.S.A., INC. | $449.83 | 2019-2025 | Entyvio, Eohilia |
| Celgene Corporation | $388.27 | 2022-2024 | Zeposia |
| Janssen Biotech, INC. | $367.00 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $328.17 | 2019-2024 | Xifaxan, Trulance |
| Lilly USA, LLC | $197.58 | 2024-2025 | Omvoh |
| Medical Device Business Services, INC. | $146.58 | 2024 | Linx Reflux Management System |
| Madrigal Pharmaceuticals | $126.94 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $124.31 | 2019-2025 | |
| Gilead Sciences, INC. | $106.88 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $91.23 | 2019-2024 | Dificid, Zinplava |
| Aimmune Therapeutics, INC. | $74.26 | 2024-2025 | Zenpep |
| Ironwood Pharmaceuticals, INC | $70.42 | 2019-2023 | Linzess |
| Boston Scientific Corporation | $70.33 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $64.76 | 2022-2025 | Suflave, Sutab |
| Redhill Biopharma INC. | $57.40 | 2020-2023 | Talicia |
| Phathom Pharmaceuticals, INC. | $54.53 | 2024-2025 | Voquezna |
| Laborie Medical Technologies Corp. | $51.75 | 2024 | |
| Daiichi Sankyo INC. | $45.00 | 2019-2021 | |
| Ardelyx, INC. | $42.12 | 2022-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $35.24 | 2025 | Iqirvo |
| Evoke Pharma, INC. | $29.54 | 2021-2023 | Gimoti |
| Celltrion USA INC. | $28.33 | 2023-2024 | Zymfentra, Yuflyma |
| Qol Medical, LLC | $27.31 | 2021 | |
| Exact Sciences Corporation | $21.25 | 2025 | Cologuard Collection Kit |
| Genzyme Corporation | $20.00 | 2023 | |
| Blueprint Medicines Corporation | $19.46 | 2023 | Ayvakit |
| Ferring Pharmaceuticals INC. | $19.25 | 2023 | Rebyota |
| Biocon Biologics INC | $18.18 | 2025 | Yesintek |
| Capsovision, INC. | $17.23 | 2023 | Capsocam Plus |
| Allergan, INC. | $15.50 | 2019 | |
| Endo Pharmaceuticals INC. | $14.33 | 2019 | |
| Shionogi INC | $13.15 | 2019 | |
| Nestle Healthcare Nutrition INC. | $12.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oren Bernheim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.